LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Inicio・Lista de Acciones・Sanofi

Sanofi

Abierto

53.02 -0.43

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

52.97

Máximo

53.52

Métricas clave
By Trading Economics
Ingresos	1.7B 2.8B
Ventas	2.8B 14B
P/B Media del Sector	30.71 104.138
BPA	2.25
Margen de beneficio	19.884
EBITDA	2.2B 4.2B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+22.02 upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	136B
Apertura anterior	53.45
Cierre anterior	53.02

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

52.4 / 52.98 Soporte y Resistencia

Sanofi Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 oct 2024, 16:07 UTC

Adquisiciones, fusiones, absorciones

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion -- Update

25 oct 2024, 05:44 UTC

Ganancias

Sanofi Profit, Sales Beat Estimates

21 oct 2024, 08:29 UTC

Adquisiciones, fusiones, absorciones

Sanofi Enters Exclusive Talks With CD&R Over Consumer Business Stake Sale -- 2nd Update

21 oct 2024, 06:31 UTC

Adquisiciones, fusiones, absorciones

Sanofi Enters Exclusive Talks With CD&R Over Opella Stake Sale -- Update

21 oct 2024, 06:13 UTC

Adquisiciones, fusiones, absorciones

Sanofi Expects Faster Earnings Growth Without Opella

21 oct 2024, 06:02 UTC

Adquisiciones, fusiones, absorciones

Sanofi Enters Exclusive Talks With CD&R Over Opella Stake Sale

17 oct 2024, 16:21 UTC

Adquisiciones, fusiones, absorciones

PAI Partners Submits Improved Bid on Sanofi's Consumer Unit

16 oct 2024, 16:03 UTC

Adquisiciones, fusiones, absorciones

Sanofi in Talks With French Government to Address Concerns on Opella Deal

11 oct 2024, 11:33 UTC

Adquisiciones, fusiones, absorciones

Sanofi in Talks to Sell Controlling Stake in Consumer Health Arm to CD&R -- 2nd Update

25 oct 2024, 20:25 UTC

Ganancias

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 oct 2024, 13:12 UTC

Ganancias

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 oct 2024, 07:00 UTC

Charlas de Mercado

Ganancias

Adquisiciones, fusiones, absorciones

Sanofi's 3Q Results Show Solid Vaccine Performance -- Market Talk

25 oct 2024, 05:30 UTC

Ganancias

Sanofi 3Q Adj EPS EUR2.86

25 oct 2024, 05:30 UTC

Ganancias

Sanofi 3Q FCF EUR3.33B

25 oct 2024, 05:30 UTC

Ganancias

Analysts Saw Sanofi 3Q Business Operating Income at EUR4.03B

25 oct 2024, 05:30 UTC

Ganancias

Sanofi 3Q Business Net Profit EUR3.59B

25 oct 2024, 05:30 UTC

Ganancias

Sanofi 3Q Sales EUR13.44B

25 oct 2024, 05:30 UTC

Ganancias

Analysts Saw Sanofi 3Q Sales at EUR12.63B

25 oct 2024, 05:30 UTC

Ganancias

Sanofi 3Q Business Operating Profit EUR4.61B

21 oct 2024, 21:02 UTC

Adquisiciones, fusiones, absorciones

Sanofi Deal Jitters Imperil Stock's Big Rebound -- Barrons.com

21 oct 2024, 08:52 UTC

Acciones populares

Stocks to Watch Monday: Boeing, Kenvue and Walmart -- WSJ

21 oct 2024, 05:31 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Proposed Transaction Is Subject to Finalization of Agreements, Approvals

21 oct 2024, 05:31 UTC

Adquisiciones, fusiones, absorciones

Sanofi Adjusts 2024 View After Opella Update

21 oct 2024, 05:31 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Bpifrance Expected to Participate in Deal With 2% Stake in Opella

21 oct 2024, 05:31 UTC

Adquisiciones, fusiones, absorciones

Sanofi Expects 2024 Business EPS to Grow by at Least Low-Single Digit Excluding Opella

21 oct 2024, 05:31 UTC

Adquisiciones, fusiones, absorciones

Sanofi In Talks to Sell 50% Stake in Opella to CD&R

21 oct 2024, 05:31 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Remain Significant Shareholder in Opella

21 oct 2024, 05:31 UTC

Adquisiciones, fusiones, absorciones

Sanofi, CD&R Talks Value Opella at Enterprise Value of About EUR16B

21 oct 2024, 05:31 UTC

Adquisiciones, fusiones, absorciones

Sanofi, CD&R in Exclusive Negotiations for Sale, Purchase of 50% Stake in Opella

16 oct 2024, 10:33 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Sanofi Needs Clear Consumer Health Plan as Investors Concerns Mount -- Market Talk

Comparación entre iguales

Cambio de precio

Sanofi Esperado

Precio Objetivo

By TipRanks

22.02% repunte

Estimación a 12 meses

Media 65 USD 22.02%

Máximo 67 USD

Mínimo 63 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Sanofi Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

52.4 / 52.98Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Sanofi

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.